search
Back to results

The Safety and Efficacy of Zanubrutinib in Refractory/Relapsed Autoimmune Hemolytic Anemia

Primary Purpose

Refractory/Relapsed Autoimmune Hemolytic Anemia

Status
Not yet recruiting
Phase
Phase 2
Locations
China
Study Type
Interventional
Intervention
Zanubrutinib
Sponsored by
Institute of Hematology & Blood Diseases Hospital, China
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Refractory/Relapsed Autoimmune Hemolytic Anemia

Eligibility Criteria

6 Years - 70 Years (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Age from 6 to 70 Diagnosis of Coombs-negative AIHA Diagnosis of warm AIHA, mixed AIHA or Evans syndrome. Meets the criteria of relapsed / refractory AIHA ECOG ≤ 3 Willing and able to comply with the requirements for this study and written informed consent. Exclusion Criteria: Diagnosis of any of the following diseases: Cold agglutinin disease, cold agglutinin syndrome, mixed AIHA, paroxysmal cold hemoglobinuria (PCH). Diagnosis of active stage of connective tissue disease. History of lymphoproliferative tumors or any other malignant. Diagnosis of other inherited or acquired hemolytic diseases. Secondary AIHA caused by drugs or infection. Previously received organ or stem cell transplantation. History of thrombosis or organ infarction. Received rituximab within 8 weeks before enrollment. Previously treated with BTK inhibitor ≥ 2 weeks. Received low-molecular-weight heparin or warfarin within 1 week before enrollment and need to continue the drug treatment. Received CYP3A4 Enzyme Inhibitors or Inducers within 1 week before enrollment and need to continue the drug treatment. Uncontrolled systemic fungal, bacterial, or viral infection (defined as ongoing signs/symptoms related to the infection without improvement despite appropriate antibiotics, antiviral therapy, and/or other treatment), known human immunodeficiency virus (HIV), known evidence of active infectious hepatitis B, and/or known evidence of active hepatitis C. Any severe and/or uncontrolled medical conditions: refractory hypertension, clinically significant cardiac diseases, renal diseases, liver diseases and metabolic diseases, etc. History of mental illness. Participation in another clinical trial within 4 weeks before the start of this trial. Pregnant or breast-feeding patients. Patients considered ineligible for the study by the investigator for reasons other than the above.

Sites / Locations

  • Regenerative Medicine Center

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Zanubrutinib

Arm Description

Each recruited subject will accept Zanubrutinib treatment.

Outcomes

Primary Outcome Measures

Overall response rate
The percentage of patients achieved complete response, complete response with incomplete hemolysis recovery, and partial response.

Secondary Outcome Measures

Incidence of adverse events and severe adverse events
Relapse free survival rate

Full Information

First Posted
August 27, 2023
Last Updated
August 27, 2023
Sponsor
Institute of Hematology & Blood Diseases Hospital, China
search

1. Study Identification

Unique Protocol Identification Number
NCT06021977
Brief Title
The Safety and Efficacy of Zanubrutinib in Refractory/Relapsed Autoimmune Hemolytic Anemia
Official Title
A Phase II, Single Center, Open-label Trial to Determine the Safety and Efficacy of Zanubrutinib in Refractory/Relapsed Autoimmune Hemolytic
Study Type
Interventional

2. Study Status

Record Verification Date
August 2023
Overall Recruitment Status
Not yet recruiting
Study Start Date
September 1, 2023 (Anticipated)
Primary Completion Date
September 30, 2025 (Anticipated)
Study Completion Date
December 31, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Institute of Hematology & Blood Diseases Hospital, China

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The sample size of this study is calculated based on Simon's two-stage design. The first stage of the study enrolled a cohort of 12 patients. If after 12 weeks at least 6 patients achieved a response, then enrollment was expanded to a total of 26 patients. The null hypothesis was unaccepted if more than 14 of 26 patients achieved the response. Accounting for a 20% dropout rate, the estimated final sample size was 33 patients.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Refractory/Relapsed Autoimmune Hemolytic Anemia

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
33 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Zanubrutinib
Arm Type
Experimental
Arm Description
Each recruited subject will accept Zanubrutinib treatment.
Intervention Type
Drug
Intervention Name(s)
Zanubrutinib
Intervention Description
Zanubrutinib was specifically designed to deliver complete and sustained inhibition of the BTK protein by optimizing bioavailability, half-life, and selectivity.
Primary Outcome Measure Information:
Title
Overall response rate
Description
The percentage of patients achieved complete response, complete response with incomplete hemolysis recovery, and partial response.
Time Frame
within 12 weeks
Secondary Outcome Measure Information:
Title
Incidence of adverse events and severe adverse events
Time Frame
within 24 weeks
Title
Relapse free survival rate
Time Frame
within 48 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
6 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age from 6 to 70 Diagnosis of Coombs-negative AIHA Diagnosis of warm AIHA, mixed AIHA or Evans syndrome. Meets the criteria of relapsed / refractory AIHA ECOG ≤ 3 Willing and able to comply with the requirements for this study and written informed consent. Exclusion Criteria: Diagnosis of any of the following diseases: Cold agglutinin disease, cold agglutinin syndrome, mixed AIHA, paroxysmal cold hemoglobinuria (PCH). Diagnosis of active stage of connective tissue disease. History of lymphoproliferative tumors or any other malignant. Diagnosis of other inherited or acquired hemolytic diseases. Secondary AIHA caused by drugs or infection. Previously received organ or stem cell transplantation. History of thrombosis or organ infarction. Received rituximab within 8 weeks before enrollment. Previously treated with BTK inhibitor ≥ 2 weeks. Received low-molecular-weight heparin or warfarin within 1 week before enrollment and need to continue the drug treatment. Received CYP3A4 Enzyme Inhibitors or Inducers within 1 week before enrollment and need to continue the drug treatment. Uncontrolled systemic fungal, bacterial, or viral infection (defined as ongoing signs/symptoms related to the infection without improvement despite appropriate antibiotics, antiviral therapy, and/or other treatment), known human immunodeficiency virus (HIV), known evidence of active infectious hepatitis B, and/or known evidence of active hepatitis C. Any severe and/or uncontrolled medical conditions: refractory hypertension, clinically significant cardiac diseases, renal diseases, liver diseases and metabolic diseases, etc. History of mental illness. Participation in another clinical trial within 4 weeks before the start of this trial. Pregnant or breast-feeding patients. Patients considered ineligible for the study by the investigator for reasons other than the above.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Weiwang Li, PhD
Phone
15332132036
Email
liweiwang@ihcams.ac.cn
First Name & Middle Initial & Last Name or Official Title & Degree
Jingyu Zhao, MPH
Phone
13752253515
Email
zhaojingyu@ihcams.ac.cn
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Liwei Fang, MD
Organizational Affiliation
Institute of Hematology & Blood Diseases Hospital, China
Official's Role
Principal Investigator
Facility Information:
Facility Name
Regenerative Medicine Center
City
Tianjin
State/Province
Tianjin
ZIP/Postal Code
300131
Country
China
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jingyu Zhao
Phone
13752253515
Email
zhaojingyu94@ihcams.ac.cn

12. IPD Sharing Statement

Learn more about this trial

The Safety and Efficacy of Zanubrutinib in Refractory/Relapsed Autoimmune Hemolytic Anemia

We'll reach out to this number within 24 hrs